Searle
Executive Summary
Company ends further enrollment into its Phase III OPUS-TIMI 16 trial for the anticoagulant orbofiban due to an unexpected excess of early (30 day) mortality in one of two active treatment arms. Searle maintained that the early adverse events were balanced by encouraging results observed between three and six months with orbofiban and by no excess mortality after 30 days of treatment. The 8,000 patients already enrolled will continue in the study